A Phase 1/2 Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors
What is the purpose of this trial?
This is an open-label, multicenter, multi-dose escalation and dose expansion study in subjects with selected advanced solid tumors (Part A), advanced recurrent immune checkpoint refractory non-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer (Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study nab-paclitaxel or Nal-IRI/5FU/LV will be administered subsequent to CM24 and nivolumab.
- Trial withFamewave Ltd.
- Start Date06/14/2022
- End Date02/05/2024
- Last Updated06/15/2022
- Study HIC#2000029869